Intermittent fasting alters tumor burden, autophagy, and metabolites in chronic lymphocytic leukemia

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

clinicaltrials.gov, ID Number NCT04626843

Funding Statement

Thank you to the BC Cancer Foundation (F2005888 to E.S. and N.M.) and to the Canadian Institutes of Health Research (PJT192015 to J.J.L.) for funding this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Harmonized research ethics board approval was granted on May 26, 2020, with the University of British Columbia-BC Cancer Research Ethics Board as the harmonized board of record and the University of Victoria as the harmonized partner board (REB Number H19-03072).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes